 Calithera Biosciences Inc NASDAQ: CALA has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited NYSE: TAK. The transaction terms include a total upfront cash payment to Takeda of 10 million and 35 million in Calithera Series A preferred stock. 